Mad Money w/ Jim Cramer 1/13/25

Summary

Mad Money w/ Jim Cramer – Episode Summary (January 13, 2025)

Released on January 14, 2025

Podcast Information:

• Title: Mad Money w/ Jim Cramer
• Host: CNBC’s Jim Cramer
• Description: “Mad Money” takes viewers inside the mind of one of Wall Street’s most respected and successful money managers for free. Cramer serves as a personal guide through the complexities of Wall Street investing, helping listeners navigate opportunities and pitfalls with the primary goal—to help them make money. The show features Cramer’s fiery opinions and the popular Lightning Round, where he provides buy, sell, and hold recommendations on various stocks.

---

I. Introduction and Market Overview

[00:00 – 07:19] Jim Cramer opens the episode by introducing Venu, a company listed on the NYSE American, which is disrupting the multi-billion-dollar live music industry by owning and operating upscale music venues. He highlights Venu's impressive financials, including $166 million in assets and a projected revenue of $200 million in 2025, representing a 56% year-over-year growth.

Cramer then delves into broader market sentiments, expressing frustration with recent government interventions in the tech and semiconductor sectors. He criticizes the Biden administration for imposing restrictions on Nvidia’s GPU sales, limiting them to 18 friendly nations. Cramer emphasizes the detrimental impact of such policies on innovation and international cooperation, stating:

“...this 200-page set of rules has become the hallmark of the Biden administration's attempt to treat our businesses as the enemy...” [00:48]

He further discusses the challenges faced by drug companies under the Inflation Reduction Act (IRA), particularly focusing on Bristol Myers’ struggle with price controls on Eliquis. Cramer underscores the importance of pharmaceutical innovation, especially in treating severe conditions like schizophrenia, heart disease, and cancer.

II. Government Policies Affecting Tech and Pharma Industries

Cramer criticizes the U.S. government's approach to regulating the semiconductor industry, highlighting Nvidia CEO Jensen Huang's efforts to promote sovereign AI among allied nations. He laments that the administration's restrictive policies are stifling Nvidia's global initiatives:

“...Jensen Wong has spent a huge amount of time going around the globe... but the government's effectively ended it by fiat...” [00:48]

Similarly, in the pharmaceutical sector, Cramer voices concerns over the IRA's impact on drug pricing and innovation. He cites Bristol Myers' CEO Chris Berner, who argues that imposed price caps on Eliquis do not reflect its substantial clinical value:

“...the imposed Eliquis maximum fair price does not reflect the substantial clinical and economic value of this essential medicine...” [07:19]

Cramer emphasizes the tension between fostering innovation and implementing regulatory measures, suggesting that such policies may ultimately harm both businesses and consumers.

III. Lightning Round Stock Picks

[07:19 – 11:24]

In the popular Lightning Round segment, Cramer interacts with callers seeking advice on specific stocks:

1. Caller Arthur from Pennsylvania: Holding AMD shares since October that have only declined. Cramer advises a hold, citing AMD’s current challenges in securing significant contracts and effective competition. He remarks:

   “I think it's just a hold. I wish I could say it's a buy, but I just don't feel I can go there.” [07:24]

2. Caller Rich from Texas: Previously profited from United Airlines, Rich now brings Builder First Source to the table. Cramer acknowledges Rich's success and humorously comments on his potential role as a co-host:

   “What can. And he's from Texas. Can't beat that either.” [08:20]

3. Additional Callers: Cramer addresses various other stock inquiries, including Kraft Heinz, Ralph Lauren, and Arbutus Biopharma, often blending market insights with personal anecdotes and humor.

IV. Interview with Bristol Myers CEO Chris Berner

[11:18 – 19:56]

Jim Cramer sits down with Chris Berner, CEO of Bristol Myers Squibb (BMS), to discuss the company's recent turnaround and innovative drug pipeline.

Key Highlights:

• Company Turnaround: Under Berner's leadership, BMS has seen a 40% stock rally from its July lows. Despite facing major patent expirations, the company received approval for a revolutionary new schizophrenia drug, Cobenfi, praised for its efficacy and reduced side effects.

  “...Cobenfi, great efficacy, on par with existing therapies. But you don't get those side effects.” [14:11]

• Drug Pipeline and Innovation: BMS is actively expanding its pipeline with potential new indications for Cobenfi, including bipolar mania and Alzheimer's disease psychosis. Berner emphasizes the unmet needs in these areas and the importance of developing drugs that offer significant clinical benefits without adverse side effects.

• Financial Strategy: Despite upcoming loss of exclusivity (LOE) for Eliquis, BMS is confident in its robust financial position. Berner outlines the company's strategy to sustain growth through a young portfolio of assets, new catalysts, and external innovation sourcing. He reassures investors about the company's ability to maintain attractive dividends.

  “We have a strong financial position that gives us the ability to give money back to shareholders through an attractive dividend...” [16:32]

• Oncology Advancements: BMS remains committed to oncology, particularly immuno-oncology and cell therapy. The acquisition of Raise Bio, a leader in radiopharmaceuticals, is highlighted as a strategic move to enhance their solid tumor oncology platform.

Cramer expresses admiration for Berner's bold approach to tackling complex diseases, noting:

“People know I doubted you on brain. I said, come on, don't go after brain. But no one can solve the brain. But you went for it.” [19:48]

V. Interview with Boston Scientific CEO Mike Mahoney

[21:24 – 29:08]

Cramer engages with Mike Mahoney, CEO of Boston Scientific, focusing on the company's impressive product lineup and market positioning.

Key Highlights:

• Company Performance: Mahoney highlights Boston Scientific's exceptional growth in 2024 and outlines plans for continued expansion in 2025 and beyond. The company boasts eight businesses, each outperforming market peers.

• Flagship Products:

  • Faripulse: A transformative treatment for atrial fibrillation (AFIB), Faripulse offers a safer and faster procedure compared to competitors. Mahoney emphasizes its efficacy and hospital adoption:

    “Ultimately, it's a safer procedure. So people with AFIB who are younger... it's a safer procedure.” [23:18]

  • Watchman: Designed to further reduce stroke risk in AFIB patients, Watchman allows patients to discontinue blood thinners, enhancing their quality of life. Mahoney elaborates on its market potential and clinical benefits:

    “Watchman's a market that we created, and it'll be well over a $2 billion market this year.” [24:53]

• Innovation and Acquisitions: Boston Scientific continues to prioritize innovation through organic research and strategic acquisitions. The recent acquisition of Bolt, specializing in intravascular ultrasound, strengthens their coronary artery disease treatment portfolio.

  “We have platforms. So we have cell therapy in oncology. That's going to continue to generate opportunities.” [17:54]

• Market Leadership: Mahoney asserts Boston Scientific's leading position in multiple medical device sectors, including endoscopy, urology, neuromodulation, and interventional oncology.

Cramer lauds Mahoney's strategic foresight and the company's comprehensive product offerings:

“Others are spending billions on new drugs. They don't have that kind of pipeline. You had the foresight to be involved with Watchmen very early on.” [25:58]

VI. Interview with Medtronic CEO Jeff Martha

[29:35 – 37:05]

Cramer converses with Jeff Martha, CEO of Medtronic, exploring the company's advancements in medical devices and upcoming innovations.

Key Highlights:

• Recent Approvals: Medtronic recently received CE marks for an adaptive Deep Brain Stimulation (DBS) device for Parkinson's disease in Europe. This device features real-time algorithm adjustments, enhancing therapy efficacy and patient quality of life.

  “...our technology can sense signals in the brain. Now we got the algorithm approved that allows for real-time adjustments to the therapy automatically.” [30:43]

• Hypertension Treatment: Medtronic addresses hypertension, a leading cause of death worldwide. Their minimally invasive procedure for hypertension has gained outpatient procedure payment approval, poised for widespread adoption.

  “This is going to be an outpatient procedure.” [32:21]

• Pain Management Innovations: The company is developing spinal cord devices that sense pain signals and adjust therapy in real-time, classified as Brain-Computer Interface (BCI) devices, marking a significant advancement in pain management.

  “That's a brain computer interface device. It's now classified as a BCI.” [33:07]

• Collaborations and Partnerships: Medtronic emphasizes its collaborative approach, partnering with companies like SpaceX and Siemens Healthineers to enhance their surgical and imaging capabilities. These partnerships aim to deliver comprehensive solutions across the healthcare ecosystem.

• Market Position and Growth: Despite market challenges and competitive pressures, Medtronic remains committed to innovation and broad portfolio expansion. Cramer questions the current stock valuation, to which Martha responds by outlining the company's growth strategies and commitment to delivering value to shareholders through dividends and revenue growth.

Cramer commends Medtronic's dedication to tackling formidable health challenges:

“People have to realize that most people stop because they don't know that they have anything wrong.” [32:57]

VII. Final Lightning Round and Market Commentary

[37:26 – 43:07]

In the concluding Lightning Round, Cramer fields rapid-fire questions from callers, providing quick takes on various stocks:

1. Caller Brett from California: Inquires about Kraft Heinz. Cramer expresses a bearish outlook, criticizing the brand portfolio:

   “Those guys should continue to go lower and they are living up their expectations.” [38:01]

2. Caller from New Jersey: Compliments Cramer's leadership but shifts the focus to Ralph Lauren. Cramer praises the brand's enduring design and market presence:

   “They've got tremendous design. It's time-honored.” [38:30]

3. Other Callers: Discussions include Arbutus Biopharma (Cramer labels it a speculative “three dollar stock”), Alaska Airlines (Cramer gives a positive outlook), and Crown Castle (Cramer advises caution, expressing skepticism about recent managerial recommendations).

VIII. Final Market Insights and Quantum Computing Commentary

[43:07 – 46:46]

Cramer wraps up the episode with a critical analysis of the quantum computing sector, highlighting the recent downturns of companies like Rigetti Computing, IonQ, and D-Wave Quantum. He attributes these declines to speculative trading reminiscent of the Gamestop short squeeze, exacerbated by misleading optimism from industry leaders like Jensen Huang and Mark Zuckerberg.

“...the Gamestop short busting story all over again. The gamers come in early, usually between 4 and 6 am they buy and they buy and they buy some more.” [46:46]

Cramer warns investors about the unsustainable nature of such speculative bubbles, advocating for a more grounded approach to investing in technology sectors. He stresses the importance of aligning investments with fundamental value rather than short-term hype.

IX. Conclusion

Jim Cramer concludes the episode by reiterating his mission to educate and empower investors, encouraging listeners to stay informed and cautious amidst market volatility and speculative trends.

“As always, the bull market somewhere promise I find just for you right here on Mad Money.” [46:46]

---

Notable Quotes:

• Jim Cramer on Government Policies:

  “My mission is simple to make you money. I'm here to level the playing field for all investors.” [00:48]

• Chris Berner on BMS Strategy:

  “We are focused on long-term growth and reshaping BMS to be one of the fastest-growing companies in the sector by the end of the decade.” [12:11]

• Mike Mahoney on Faripulse:

  “It's our largest business in 2025. We'll be number two in 2025, and then we're aiming to be number one shortly thereafter.” [23:18]

• Jeff Martha on Medtronic’s DBS for Parkinson's:

  “Our technology can sense signals in the brain... allows for real-time adjustments to the therapy automatically.” [30:43]

• Jim Cramer on Quantum Computing Bubble:

  “I'm glad they popped the bubble because the quantum computing companies are such money losers...” [43:07]

---

This comprehensive summary captures the essence of the January 13, 2025 episode of "Mad Money w/ Jim Cramer," highlighting key discussions on market trends, government policies, innovative advancements in the healthcare sector, and insightful stock recommendations. The inclusion of notable quotes with specific timestamps provides depth and context, ensuring that both regular listeners and newcomers can grasp the critical insights shared during the episode.

Transcript

[Jim Cramer]

Meet Venu on the NYSE American Symbol Venu disrupting a multi billion dollar live music industry. Venu owns and operates upscale music venues.

[Chris Byrne]

Outdoor amphitheaters with seven revenue sources $166 million in assets Luxury suite sales of $77 million in 2024 $200 million expected in 2025 56% year over year Growth.

[Jim Cramer]

Venue on the NYSE American Venu @.

[Capella University Representative]

Capella University Learning the right skills could make a difference. That's why our business programs teach you relevant skills you can take from the course room to the workplace. A different future is closer than you think with Capella University. Learn more at Capella. Edu.

[Jim Cramer]

My mission is simple to make you money. I'm here to level the playing field for all investors. There's always a bull market somewhere and I promise to help you find it. Mad Money starts. Hey, I'm Kramer. Welcome to Mad Money coming to you from San Francisco. Welcome to Cramerica. I'll be my friends. I'm just trying to make a little money. My job is not just entertainment, but to educate and teach you. So call me at 1-800-7-for3 CNBC or tweet me at Jim Cramer. What a relief to cover science and computing only for a few days. I mean, that's right. On a day when The Dow gained 359 points, S&P advanced.16% and the Nasdaq lost 0.38%. We came to San Francisco for the JP Morgan Health Care Congress to see the future of medicine. I got to I liked what I saw. At the same time, I sure didn't like what I saw when I watched the Joe Rogan Experience this weekend when a very unfettered Mark Zuckerberg, the founder and CEO of Meta Platforms, took some shots. I would say cheap shots. I mean, just terrible. At Apple, that made me want to throw a yellow flag 15 yards on sportsmanlike conduct. Worse, the US government chose to meddle in the semiconductor world in a way that defeats so much of what Jensen Wong, the CEO of Nvidia, is trying to accomplish. A series of restrictions came out this weekend that put limits on the number of GPUs Nvidia can sell to all but 18 friendly nations. Look, we all get the game. We're trying to stop China from getting as many advanced chips as possible. I admit that's okay, but this 200 page set of rules has become the hallmark of the Biden administration's attempt to treat our businesses as the enemy and videos cooperative with the federal government. Every step of the way. Jensen Wong has spent a huge amount of time going around the globe though, trying to work with all of the friendly governments, not just 18, to help them create sovereign AI. He knows that America could control everything. That's how powerful we are. But he wants to empower other nations so they don't get subsumed by us. He doesn't want to be the ugly American who dictates the things the way we did during the Cold War. It's one of the best initiatives he's worked on and now the government's effectively ended it by fiat. Look, you know that I'm no fan of the Chinese government, but the US needs friends. Wang is the ultimate ambassador of goodwill. This move is embarrassing, shortsighted, demeaning and ultimately a fitting coda to administration that seems to have it in for business at every turn. Unless it's clean energy, of course. Of course. The government's no friend of the exacts I'm meeting out here either. I'm sitting down with some of the best health care CEOs in the world today. Bristol Myers, Boston Scientific, Medtronic. Companies that spending billions of dollars in research and development to tackle the hardest brain, heart, bone and blood based diseases. Yet they had a bullseye on their backs too with the Biden administration targeting some of the biggest drugs as part of the so called Inflation Reduction Act. I know lots of people believe that the drug companies prey on our nation. And look, no industry's perfect. But when I talk to these execs, they're doing their best to tackle major unmet medical needs, fatal needs. When I sat in front of Chris Byrne, the CEO of Bristol Myers, and listen to what his company's doing for schizophrenics. I wonder why the government is cramming down the price of Eliquis, the medicine designed to prevent strokes. As Bristol said in a release about the new rule, quote, the imposed Eliquis maximum fair price does not reflect the substantial clinical and economic value of this essential medicine which is widely regarded for its effectiveness in reducing stroke related events, hospitalizations and extended rehabilitation needs, end quote. Bristol notes that this leading coagulant is, quote, relied upon by millions of Americans daily and is the most prescribed medicine on the IRA list, not the most expensive, end quote. Like with Tech, the CEOs of the drug companies here were Persona non grata at the White House for the last four years. But if you don't give Bristol Myers a return, how the heck can it spend $14 billion to buy a company with a drug that might or might not work in diseases of the brain. The brain is really hard to crack. I worried that Bristol Myers was making a big mistake when it bought Karuna Therapeutics even as I cheered the attempt to go after the intractable. You can't go after the intractable without the profits from Eliquis. And believe me when I say it's not the cost of Eliquis that's the problem in this system. It's pretty much everyone else that takes money but offers nothing of real value. I say that as someone who actually is trying to develop a drug. It is like trying to get things going. The cost of a clinical trial is astronomical. Most drugs fail. It's not enough that all these tech and drug companies are targets of the Biden administration. They can become targets of each other. Which brings me to Mark Zuckerberg's interview with Joe Rogan, where Zuckerberg trotted out some old canards about how Apple's developed nothing serious since Steve Jobs died. Arguing that it stifles innovation puts a tax on developers who sell in the App Store. Look, I like both companies very much. I think they do fabulous work. But it's a cheap shot to say Apple's done nothing since Jobs. Its products are loved by companies. It's got the highest customer satisfaction rates of any large scale brand. Billions of people use them. As someone who has loved Apple and its accoutrements, I find these comments self serving and one sided. To put it simply, Zuckerberg said the things I heard nonstop from the Justice Department's antitrust division these last four years. Sure, Apple does some things that make it hard for people to leave their ecosystem. If Apple were to ease up its grip on the App Store, then Meta could make much more money and users might be happier. There's some truth there, but Apple's not stopping anyone else from developing a better system. At the end of the day, they invented the App Store. They can do what they want with it now. Every company has its problems and there are things Apple does that we don't like, that I don't like. There are things Meta does that we don't like that I don't like. I was just surprised to hear such a public thrashing. If I were Mark Zuckerberg, I would not be helping the Justice Department go after Big tech. Bad president for Meta. These Silicon Valley guys, they got no sense of a murta. Zuckerberg blasted the TV media for not understanding things and using sound bites to make them look bad. As someone who spent years defending this guy on Air I was surprised he went there. In the end. He made it real easy for the Justice Department by trashing Apple. And maybe that was what he wanted to do. We are in some weird moment where the two best industries we have are in the crosshairs of the federal government, with Mark Zuckerberg aiding and abetting the prosecution. The drug companies managed to rally today because we heard their side of the story. But tech, the tag team of the government of Meta, may have been too much for everyone. At the end of the day, though, buyers finally came in to find bargains in the semis. And software and the drug stocks, or only the drug stocks, finished in the green. The bottom line, are the charges against these two industries just glancing blows? Nah. This was just one day where the bond market didn't crush every stock. Only the government. And yes, Metta did that job. Let's go to Arthur in Pennsylvania. Arthur. Arthur.

[Caller (Arthur)]

Hey, Jimmy, chill. How are you doing?

[Jim Cramer]

I'm doing well, chief. What's happening?

[Caller (Arthur)]

So I've been holding on to these shares since October. Very bullish intent. Since buying, it's been red, nothing but red, and more recently, more red. What's your take on amd? Buy, hold, sell. What should I do?

[Jim Cramer]

Right now AMD is doing okay. It's having trouble catching up to in video, frankly, I've got to tell you, it's. It didn't get a big Amazon contract. It spent a lot of money on a couple of things don't seem to be working right now. I think it's just a hold. I wish I could say it's a buy, but I just don't feel I can go there. Let's go to Rich in Texas. Rich.

[Caller (Arthur)]

Hey, Jim. How are you doing today?

[Jim Cramer]

I am doing well. How about you?

[Caller (Arthur)]

All right. Hey, last year I was on your show several times talking about the undervalued United Airlines with solid fundamentals and went from $38 to 105. Maybe you remember me.

[Jim Cramer]

You got horse sense.

[Caller (Arthur)]

This year I'm bringing you Builders first source.

[Jim Cramer]

No, you're not, because we talked about it today. You are absolutely right. This guy. I need a co host, man. I'm tired. Rich is now my co host. I'm just making. He's got. He did United. Now he's doing builder first source. What can. And he's from Texas. Can't beat that either. Maybe the tag team of met in the US Government is what hurt tech stocks today. Or maybe it's just one day. The bond market didn't crush stocks. At least buyers are finding bargains where they can all make money. Tonight, I'm kicking off my time in San Francisco by checking up on a trio of health care players. First up for Some Eyes has been on the run since its July lows. I'm learning more about his pipeline schizophrenia drug with the CEO. Then Boston Scientific had what a stock has been great, but can it keep going higher? I'm getting a read of the road ahead with this top risk. And later, medical device company Medtronic announced a new innovation to Parkinson's treatment today, Intractable disease. I'm checking in with the CEO, so stay with Kramer.

[Mad Money Producer]

Don't miss a second of Mad Money. Follow imkramer on X. Have a question? Tweet Kramer Madmentions. Send Jim an email to madmoneynbc.com or give us a call at 1-800-743-CNBC. Miss something? Head to madmoney.cnbc.com Pandora makes it easy for you to find your favorite music. Discover new artists and genres by selecting any song or album and we'll make you a personalized station for free download on the Apple App Store or Google Play and enjoy the soundtrack to your life.

[Capella University Representative]

Is it time to reimagine your future? The right business skills may make a difference in your career. At Capella University, we offer a relevant education that's designed to focus on what you need to know in the business world. We'll teach professional skills to help you pursue your goals like business management, strategic planning and effective communication, and you can apply these skills right away. A different future is closer than you think with Capella University. Learn [e-mail].

[Mad Money Producer]

Have you ever had to put your.

[Capella University Representative]

Plans on hold due to symptoms of generalized myasthenia gravis or gmg? Like taking that weekend trip, talking with friends or enjoying a meal? Learn about a treatment option that may help. Visit treatgmg.com to learn more. That's treatgmg.com.

[Jim Cramer]

Over the last six months we've seen an incredible turnaround at Bristol Myers Squid. Under leadership of new CEO Chris Berner, the stocks rallied 40% from its lows in early July. His company's dealing with some major patent expirations, but in September they got approved for revolutionary new schizophrenia drug and that's called Cobenfi, which has far fewer side effects than anything currently available. I also like the rest of the pipeline. Lots of good stuff for cardiovascular disease, oncology, immunology and of course, neuroscience. The story's got gotten so good that we bought some Bristol Myers for the Travel Trust late last year and While we were out here for the J.P. morgan Health Care conference, we had a chance to check in with Dr. Chris Berner. He's the chairman CEO of Bristol Myers. Take a look. Chris, I love what you're doing because you are setting a foundation for long term sustainable growth. You aren't trying to make money right now. You've got a five year plan, maybe even longer. And I need you to tell our people about.

[Chris Byrne]

Well Jim, first of all, it's great to be back with you. A lot has happened since we last got together at JP Morgan. We've improved our execution. We are focused on long term growth and coming into this year we are squarely focused on reshaping BMS to be one of the fastest growing companies in the sector by the end of the decade. But we've got more work to do. It's a multi year journey.

[Jim Cramer]

Well, let's talk about Kubernetes because I think this is the possibly the biggest drug of our generation because unmet need huge standard of care now. Not great. Tell us about it.

[Chris Byrne]

Well look, we're incredibly excited about Cobenphy. We launched last September. We're off to a very good start in terms of scripts. But more important at this point Jim, is what we're hearing back from physicians and from patients. And there the feedback has been great. Patients are getting benefit on their positive symptoms, hearing voices, hallucinations, but equally importantly they're getting symptom relief also on cognition. They're able to re engage with their families disease. So we're really excited about schizophrenia. But as we talked about today here at this conference we have a string of potential new indications. One new potential indication or data readout on Coben V every year for the rest of the decade.

[Jim Cramer]

Incredible. Now I do have to deal head on. JJ been an acquisition today in the neurospace. I thought it was more for major depression but in their press release they talked about schizophrenia. Talk about bipolar. I didn't think they're the company. They have a drug from 2019 but I can't find a lot of people who are excited about it. Maybe what had you heard of it? Did you look at the company?

[Chris Byrne]

Well listen, what I will tell you is it's incredibly exciting to see the new innovation that's taking place in this space. We like to see more people focused in this because the huge unmet need that we see schizophrenia. A million and a half patients treated with schizophrenia in the US and unfortunately until called Benfi we did not have a fundamentally new mechanism of action to treat those patients. And now we do. We get efficacy on par with the best of the existing atypicals. But we don't see the side effect profile that you see with those drugs. And that's why we're so excited about Cobind.

[Jim Cramer]

Did you look at the company that J.J. bought today?

[Chris Byrne]

Well, look, we look at a lot of companies in this space. Business development is going to continue to be a priority for us. We've always sourced innovation externally. And the way we think about it is can we bring the science in? Does it make strategic sense for us? And importantly, and you referenced this earlier, can we use this science and these new products to improve the growth profile for the company as we exit this decade? That's what we're focused on.

[Jim Cramer]

I glossed over something and I apologize. When you talk about the side effect profile, I don't think people realize what's been going on, how people are treated and why they don't stay on it. Please explain to people how the drugs are hated by the, by the actual populace who has to use them.

[Chris Byrne]

Well, the unfortunate thing in schizophrenia is for decades what's happened is patients will cycle through multiple drugs until they find something that works to alleviate the positive symptoms. Hallucinations, for example. But unfortunately it carries with side effects like significant weight gain. They can't focus and that leads patients to go off therapy. And that's what we're so excited about. Cobinfi, great efficacy, on par with existing therapies. But you don't get those side effects.

[Jim Cramer]

Talk about bipolar trial, because this is another illness that affects millions of people worldwide.

[Chris Byrne]

Well, we've got a number of new indications potentially coming. We have three phase 3s starting this year, including in bipolar mania, where again, the existing standard of care are older atypicals, many used off label. And unfortunately, we haven't seen a fundamentally new mechanism in many, many decades. And there's potential here.

[Jim Cramer]

Now, how about what could be going on with Alzheimer's for you?

[Chris Byrne]

Well, what we like about one of the studies that we'll be reading out this year, we have three phase three studies with cobenfi on Alzheimer's disease psychosis. There are 6 million Americans who are diagnosed with Alzheimer's. Half of those patients get psychosis symptoms. And so we're looking to potentially use Cobenfi to treat them. Right now, most patients who have psychosis symptoms are treated again mainly off label with existing atypicals.

[Jim Cramer]

Now, I do want to talk about the, what I regard as being a safe dividend that people are concerned about because you do have a lot of loss of exclusivity situations. So. So please talk about Patton Cliff within the context of how you've got a lot of firepower and a great balance sheet. So maybe it shouldn't be a front concern given your history of a dividend.

[Chris Byrne]

Well, Jim, look, our LOE exposure for this decade is pretty well known. But here's the good news. Number one, we're not the first company to go through this. We've had our own patent losses over time. And we have a plan and we're executing that plan. And there are three components of that plan. First, we've got a young portfolio of growing assets. Grew nicely last year, good momentum. This year we have a string of new catalysts that are going to have data coming out over the next 18 to 24 months. And then you mentioned it, we're in a strong financial position. Gives us the ability to give money back to shareholders through an attractive dividend that we've paid over 90 years and go out and source innovation externally.

[Jim Cramer]

Well, let's talk about the rest of the growth portfolio. Let's talk about oncology because a lot of people say, hey, they're done. Are you done?

[Chris Byrne]

We are definitely not done in oncology. We have an exciting suite of opportunities across multiple therapeutics, including oncology. We are a leader today in immuno oncology. We made good progress extending that business potentially into the next decade. We've added to our position in targeted therapies. And importantly, Jim, we have platforms. So we have cell therapy in oncology. That's going to continue to generate opportunities. And last year when we did the deal with raised Bio, we bought into one of the fastest growing platforms in solid tumor oncology, which is radiopharmaceuticals. So we feel good about maintaining our leadership position.

[Jim Cramer]

Talk about what? Radiopharmaceuticals. It's novel. How do you feel about it?

[Chris Byrne]

We feel very good about it. We did the deal shortly after I became CEO in December of 2023. We're going to actually see the first data coming out from that platform in a couple of years with our Raise 101 program. But we think this could be a really important opportunity potentially in the long run. Displace chemotherapy.

[Jim Cramer]

Now people are going to say, jim, why didn't you mention Eliquis? Eliquis going off patent? It's going to be a disaster for them.

[Chris Byrne]

Cardiovascular is an area we have been a leader in for a long time, going back to the Plavix days. Eliquis is an important drug for us today. But we know, Jim, about 40% of patients in atrial fibrillation, for example, can't benefit from factor 10 as we have an opportunity with our drug Novexian, which is a factor 11A, one of the products that are going to be reading out over the next two years to address that unmet need in afib. We also have two other studies running in parallel.

[Jim Cramer]

Okay, I don't, I want to circle back on Cobenphy because I've done a lot of work with brain. And if you are someone, a parent of someone who has schizophrenia or unfortunately one of the people who is homeless because of schizophrenia, tell people how they can get in the trial, what do they have to do because the FDA is so in favor of this that they put out the release ahead of you.

[Chris Byrne]

Well, listen, we've got a great opportunity with schizophrenia. We have an ongoing adjunctive schizophrenia study that will read out this year. That's combination use. But if you look at the additional trials we have coming, talk to your physician, look online on clincherials.gov and you know what? We've got tremendous opportunity to help many more patients with this medicine. And it's one of many things we're working on at BMS to really transform this company and deliver top tier growth by the end of the decade.

[Jim Cramer]

Got to get the word out, out. It's really important for every city in America in the world. We know this well.

[Chris Byrne]

One of the things we love about Cobenfi, Jim, is we have a real opportunity with this medicine to change the narrative around this disease.

[Jim Cramer]

Okay, well, look, thank you for everything you do. I just. People know I doubted you on brain. I said, come on, don't go after brain. And no one can solve the brain. But you went for it.

[Chris Byrne]

Well, this is hard stuff, but it's what we do at Bristol Myers.

[Jim Cramer]

Fantastic. Chris Burner, Bristol Myers CEO. Thank you, Chris.

[Chris Byrne]

Thank you. Great to be doctor.

[Mad Money Producer]

Coming up, can Boston Scientific keep its momentum going after a banner 2024? Kramer is finding out when he sits down with the company's CEO. Next.

[Walmart Representative]

Walmart. It's Walmart plus free delivery, which saves members time plus money. Yep. Plus an included Paramount. Plus subscription to stream movies, shows, sports and that can't miss documentary plus Burger King savings. That's right. Members get 25% off Burger King digital orders every day of the week. Walmart Plus plus it's Walmart plus become a member at walmartplus.com $35 order minimum Paramount plus essential plan only. Separate registration required. Valid and participating USBKs in the BK app or bk.com for members only. 25% off one time per calendar day. Terms apply. See Walmart plus terms and conditions.

[Capella University Representative]

Is it time to reimagine your future? The right business skills may make a difference in your career. At Capella University, we offer a relevant education that's designed to focus on what you need to know in the business world. We'll teach professional skills to help you pursue your goals, like business management, strategic planning, and effective communication. And you can apply these skills right away. A different future is closer than you think with Capella University. Learn more at capella. Edu.

[Jim Cramer]

Out here in San Francisco for the annual J.P. morgan Health Care Conference. And few companies are coming to this event with more momentum than Boston Scientific, the maker of minimally invasive medical devices best known for its cardiology franchise. They've also got a big medical surgical business, too, and one that spans everything from endoscopy to urology to neuromodulation. Last year, Boston Scientific stock rallied roughly 55%, largely thanks to its new pulse field ablation system for arterial fibrillation. Now this is also known as AFIB. The stock's up another 6% year to date thanks to J and J, which just paused the launch of a competing product a couple of months after its approval after four reports of strokes. Serious stuff. I think all the focus on AFIB does a disservice to Boston Scientific. This company's about more than one product. It's got a great portfolio. I bet it can generate double digit growth across the entire business. Very rare for pharma. But don't take it from me. Earlier today we got a chance to speak with Mike Mahoney. He's the chairman and CEO of Boston Scientific. Take a look. Mike, what can I say? You are on a roll. I think that you may be in the best shape of any of the companies that I'm speaking with today. Tell us about what you're doing right now. And by the way, you have a new acquisition that we got to talk about. We do.

[Mike Mahoney]

Well, thanks for having me, Jim.

[Jim Cramer]

Sure.

[Mike Mahoney]

It's an honor to be here. Well, first of all, we're coming off of a excellent 2023 and we had even better 2024 and we aim to have a terrific 25 and beyond. I'm so proud of our the, the talent across our company. You know, the key for us is we have eight businesses. Almost all of them are growing faster than the market. But then we have two breakthrough products that are transforming health care. And product called Faripulse and Watchman that like to get into you, but that's really driving the global growth of the company.

[Jim Cramer]

Now, Faripulse, you got to talk about what it means to have the kind of market share you have. And also, unfortunately, you never want to wish badly on a competitor. But there was something that happened just this week with JJ that to me, solidifies your stand. Yeah.

[Mike Mahoney]

So the treatment of AFIB is so important. There's over 40 million patients who suffer from afib. If you have afib, your heart beats irregularly. It can cause heart failure, potentially lead to stroke, a serious condition. So Faripulse has really transformed this market. So it'll be our largest business in 2025. We've gone from the number four player. We'll be number two in 2025, and then we're aiming to be number one short thereafter. But why Therapulse is so great for hospitals, physicians and patients. Ultimately, it's a safer procedure. So people with AFIB who are younger, people with afib, are older with comorbidities, are being treated with a ferropulse. It's a safer procedure. It's very efficacious. We've done over 200,000 of them, and hospitals love it because it's about 25 to 30% faster. So patients get in and out of the hospital more quickly, have a safe procedure, reduce the risk of stroke, reduce the risk of heart failure, and it's changing the market.

[Jim Cramer]

Well, that sounds like something that RFK Jr. Who is very concerned and worried about vaccines, and I get that. I mean, it's something that will not impact your business at all. To me, you'd be the one of the few that I disregard as safe under this new administration.

[Mike Mahoney]

Yeah. So I would say in Medtech in general, we don't have like, tremendous pricing power. We typically have flattish price, and we deliver products that are clinically tested, have excellent safety track record, and are, you know, significantly beneficial to patients.

[Jim Cramer]

Now, Watchman, we've got to talk about. It reduces the risk of stroke. This is the big fear. People don't know about it when until they hear it. They think it's kind of boilerplate. It isn't boilerplate.

[Mike Mahoney]

No. So Watchman I'm so proud of so far, Pulse is an existing market that we're transforming. Watchman's a market that we created, and it'll be well over $2 billion market this year. We've been growing to 6 billion in a couple of years based on our clinical trials. So Watchman Is a, is a product where if you have afib, you have a higher risk of stroke. So if you get treated with ferro pulse to hopefully fix your afib, then what Watchman will do is further reduce, reduce your risk of stroke and allow patients who are indicated to get off blood thinners so to go back to live a normal life and active life without the fear and risk of bleeding that so many patients have.

[Jim Cramer]

So we gotta drill down on that because I think people have to understand that an older person is fearful after the pulse field ablation that they might fall because they could be so anywhere and bleed out very quickly.

[Mike Mahoney]

Yes. So I may be hipaa, but my mother just received a Watchman device and the reason she did it, she wanted to reduce her risk of stroke. But she wanted to walk her dog. She wanted to walk her dog in the wintertime, she wanted to risk of falling. So being able to get off blood thinners reduce your risk of stroke in a procedure that takes less than an hour and you're out of the hospital in the same day.

[Jim Cramer]

Now, one of the things that you do well that others don't. Other companies are spending billions on new drugs. They don't have that kind of pipeline. You had the foresight to be involved with Watchmen very early on.

[Mike Mahoney]

Yeah, yeah. So what we do is we think about innovation all the time. And that's the key for our business. All about innovation in your people and the culture of the company. And so we're positioning the company to be great and differentiate for the next 10 years. So one way we do that, besides our organic R and D, is we have the largest venture portfolio in Medtech. So this year in 24, we did nine new investments in our venture portfolio. And our venture portfolio is 45 companies. These are very early stage companies. And historically we have acquired about a third of those companies from our venture portfolio. So it's another way for us to drive innovation beyond what we do organically with our internal architecture.

[Jim Cramer]

R and D. People need to know it's not all heart.

[Mike Mahoney]

No, no. We have eight different divisions. We're the largest endoscopy company in the world. We're the largest urology company in the world. We just acquired a company called Axonics to help treat women with overactive bladder. We have a large neuromodulation division. We have a large interventional oncology business, peripheral vascular. So there's eight divisions, most all of them growing well, well above their peer group.

[Jim Cramer]

So what should we be hearing about next? I mean, I was blown away at how big Watchmans could be. Talk about some of these others because I think people feel that right now you're really Farro Pulse and Watchmen, not much else. And that's really wrong.

[Mike Mahoney]

Not true at all. First of all, I will say with Ferrupulse and Watchman, now there's a procedure where you do both at the same time, which is even. That's just.

[Jim Cramer]

How many docs know how to do that?

[Mike Mahoney]

Most all electrophysiologists and about a third of the interventional cardiologists are doing that today. So there's thousands of them. So a couple other big products. So we have another product called Aging, which is a drug coated balloon for the coronaries. We just acquired a company called Bolt, which is called intravascular ultrasound.

[Jim Cramer]

Right. So patients talk about that because I thought that was really exciting and something that people were. It's pretty invasive without that.

[Mike Mahoney]

Yeah. So we have the widest portfolio to treat coronary artery disease. The plumbing in the heart. And so this is yet another tool to reduce, to reduce and break up calcium to prepare a stent procedure. And so you want to see the. See the artery, prepare and treat the artery at the same time. So we're able to visualize it with our imaging that we have various tools to treat the artery.

[Jim Cramer]

Talk about that. Because I mean, it's pretty. Frankly, I thought it was science fiction. No, I'm not kidding. It's laser based. I mean, it's kind of crazy.

[Mike Mahoney]

Essentially it's a balloon that you'll image the heart first, then you'll put a balloon where the vessel is, where there's a need for a stent and you'll actually. Lasers actually break up the calcium within the vessel. So you prepare that vessel for a stent. So that way the stent's gonna work, do its job perfectly.

[Jim Cramer]

I've got to tell you, people don't realize how hard the things that you're doing. These are things that people. Some of these were just death, they're fatalities. And you've taken this off the table when to congratulate you for all the things you're doing. Mike Loney is the chairman CEO of Boston's Identification, which by the way, is the best performing of all the companies we're going to see. But maybe with the exception of Eli Lilly, got to put them in there.

[Mike Mahoney]

We'll keep it going.

[Mad Money Producer]

All right, thank you.

[Jim Cramer]

Thank you so much. We're back in a moment.

[Mad Money Producer]

Coming up, could a new treatment for Parkinson's be on the horizon? Kramer sitting down with The CEO of Medtronic to discuss it next.

[Jim Cramer]

While we're out here in San Francisco for the JP Morgan Healthcare Conference, we got a chance to catch up with Medtronic, the huge medical device company that's focused on cardiovascular disease, neuroscience and diabetes. While this stock has been lost in the wilderness for years, it's become an intriguing option here as it's had a bunch of successful product launches. And after the sell off in recent months, it's darn cheap. Or today I sat down with Jeff, Martha, he is the chairman and CEO of Medtronic. Get a better sense of where his company's going. And you got to take a look, Jeff, you have so many things going on, but I understand you've got something right now that you want to tell me about.

[Jeff Martha]

Well, first of all, Jim, thanks for having me. We're super excited to be here at this year's JP Morgan, given all the innovation we've got coming. And the late break, it was just announced that we just announced today has to do with something you're very near and dear to your heart. A DBS for Parkinson's. We just got CE marks so approval in Europe and many other countries for what they call adaptive dbs. So like we talked about before, our technology can sense signals in the brain. Now we got the algorithm approved that allows for real time adjustments to the therapy automatically. And so that just got approved.

[Jim Cramer]

We're also millions of people with no hope. I mean, I know that you've got something. You're actually the pioneer in this field.

[Jeff Martha]

Right.

[Jim Cramer]

But how is this going to change lifestyle?

[Jeff Martha]

Well, first of all, instead of like, as you know, Parkinson's, it gets worse over time, right?

[Jim Cramer]

Yeah.

[Jeff Martha]

And so the DBS gets updated. The therapy we provide would get updated episodically when the patient would go back into their physician along with the Medtronic representative, and we would update the therapy for where the patient is now. Happens automatically real time every day with this adaptive. So it's better for the patient. It's also better for the healthcare system because it's a lower burden. And I do think this will help physicians, inspire them to prescribe it more because it's less of a burden on the health care system.

[Jim Cramer]

Well, congratulations. I think that you guys have historically going after the toughest thing. People don't go after Parkinson's because of the failure rate, but you often have a device way to go like you're doing with hypertension. Not enough comment on that. I hope that the government will pay because their unmet need here for Hypertension is just extraordinary.

[Jeff Martha]

It's massive. It's the number one contributor to death in the world. 50% of cardiovascular disease or stroke related death is caused by hypertension. And if you have hypertension, 75% of the people who have it don't have it under control. They stop taking their meds within one year. And so this is a new to world therapy we've talked about on the show before, got approved about a year ago from the fda. And since then we've been putting the reimbursement pieces, the puzzle pieces in place. And just January 1st, the outpatient. This is gonna be an outpatient procedure.

[Jim Cramer]

Which is incredible because it's still, they go up, I mean it's invasive versus what they.

[Jeff Martha]

Well, I don't know about invasive. Look, patients, patients. We're finding great response from patients. Mild anesthesia, you wake up, you don't know what happened, you don't feel pain. And over the next couple days and weeks your blood pressure goes down. And so we just got this outpatient procedure payment approved. And so that's the one in effect January 1st. And the last piece of the puzzle is just who is going to get covered, right? Which patients? And that's what we're working with, cms, you know, the US government as well as commercial payments payers around. And look, once we get that piece snapped in, this is going to scale.

[Jim Cramer]

Oh yeah. And I think that people don't realize that most people stop because they don't know that they have anything wrong.

[Jeff Martha]

Right. It's a silent killer. It's a silent killer.

[Jim Cramer]

Now another thing that no one wants to tackle pain, but you're doing that too.

[Jeff Martha]

Yeah, it comes back to this sensing technology. We've got it now in the brain and now for this, for the spinal cord as well. Sensing pain signals and adjusting the therapy. And we're interrogating your spinal cord 50 times a second to identify the pain because pain's hard to quantify and to adjust this, you know, you're familiar with nature, it's one of the leading clinical publications. Just once we get this approved, the CE mark approval. They also acknowledge that this is a brain computer interface device. It's now classified as a bci. Brain computer interface. And now it'll be the. You know, we've already got 40,000 people with DBS. This technology alone, so orders of magnitude the largest BCI device out there.

[Jim Cramer]

Now I have to ask you, I mean you're always working on something that I don't know that's just about to be approved. What else is in the pipe right here?

[Jeff Martha]

Well, I'd say, look, one that's we're in the moment on is afib. AFIB is, you know, it's a huge problem as people get older and they're starting to outlive their hearts.

[Jim Cramer]

But, but there's that competitive Boston Scientific lead right now. J and J though looks like they're, let's just say, in trouble for what they.

[Jeff Martha]

Yeah, look, I think they're the J and J is the incumbent with the, the previous technology which, which worked fairly well. But this new technology that Boston Scientific and Medtronic are advancing is a step forward. And you know, we're the two leaders here. Boston got here first but we've got the big share, they get big market share in this year, but we've got a more comprehensive portfolio and we believe our latest technology known as Afera is the highest in band from Physicians and we're scaling that now.

[Jim Cramer]

You are willing to take on diabetes in a way no one else is other than Abbott. And congratulations to you for willing to work with, be an opponent to make it for the patient.

[Jeff Martha]

Right. Look, technology, some of the problems with healthcare in the industry is we come out with point solutions that work in a niche way. If you're really gonna have impact, you got to work across the ecosystem, broader solutions. And for us that means working with other companies. We've worked, we just talked about, we work with SpaceX even outside our industry, inside the industry. We just announced recently, a couple months ago, partnership with Siemens, the Siemens healthineers, how we could take imaging and help our surgical business. And then recently Abbott, who's a competitor to help with our diabetes solution.

[Jim Cramer]

It is worth mentioning that you did work with Elon Musk during the COVID epidemic and he seemed to be someone pretty knowledgeable.

[Jeff Martha]

He was extremely knowledgeable. I was blown away. Like this is a valve that we had trouble procuring for our ventilators back in the ventilator crisis. And it just so happened SpaceX was making that same valve for their spacecraft that have life support systems in them.

[Jim Cramer]

Well, I've got to tell you, we just go over all the different things that you are working on and I'm talking about ablation cardio, diabetes. But I've got to tell you Jeff, the one thing I don't understand, $80 for a company that's got consistent mid single digit, maybe even high single digit growth for a lot micro for instance. I don't get it. I don't get what your stock's still doing at 80.

[Jeff Martha]

Well look what we can do. We control. We can control right now. We're driving a lot of innovation that's going to get our top line. The financial algorithm that we're shooting for and we're committed to is that at the very least that mid single digit revenue growth and then translating that revenue growth to leveraged earnings down the P and L. So we've already told the street this back half of the year we're going to have high single digit eps and then you add our dividend on top of that, you get to a double digit return. And so as we continue to prove that, I think the stock will take.

[Jim Cramer]

Care little personal situation. I got to go for the colonoscopy. I've asked for your AI. Well, I get it.

[Jeff Martha]

Well, it's out there scaled now. It's becoming the standard of care. So we can easily get that to you.

[Jim Cramer]

Tell us it was 18% they were missing last time I spoke to you. Apparently the number is much higher.

[Jeff Martha]

As we've gotten out there. These big GI gastrointestinology practices are realizing they're missing up to half the polyps.

[Jim Cramer]

Well, I wish I understood exactly why the profession itself is not up to what you guys are doing. But I know what you're doing is terrific. I thank you. I want to thank Jeff, Martha, CEO of Medtronic for doing everything. Thank you very much. Back in second.

[Mad Money Producer]

Coming up, Kramer takes your calls. And the sky's the limit. It's a fast fire lightning round.

[Jim Cramer]

Next. It is time. It's time for the white round creation by the sport Bradford girls in arms. She's saying the stock is held above by Bicel still disappear. Another course stocks ahead of time. My steppers Graphics you plan to sound and then the lighting round is over. Are you ready? Ski dag? Time for the light crunch. Brett in California. Brett.

[Caller (Arthur)]

Jim. Jim. What is going on with this stock? I've owned this stock as long as Warren Buffett. What is happening? Kraft, Heinz.

[Jim Cramer]

Well, what's happening? Craft. What should I craft? Heinz. That's the worst collection of brands I've ever seen. I think those guys should continue to go lower and they are living up their expectations. Let's go to Japan. Jersey in New Jersey. Jersey.

[Caller (Arthur)]

Hi, how are you sir?

[Jim Cramer]

I'm good. How about you?

[Caller (Arthur)]

I'm great. Thank you for your leadership and execution skills.

[Jim Cramer]

Oh, you're very kind. Thank you very much. I hope to bump in you someday.

[Caller (Arthur)]

Thank you sir. I'm right over here by a woodland park, so.

[Chris Byrne]

Okay, sure.

[Jim Cramer]

I'll Be over there.

[Caller (Arthur)]

Yeah, yeah. My question is I'm all about manifestation. So it just makes sense because my mom used to work for Ralph Lauren. What's the power behind Ralph Lauren?

[Jim Cramer]

Well, Ralph Lauren, first of all, great American, won the medal of freedom. But I'll tell you what, the power behind it, they've got tremendous design. It's time honored. I've got an eagle scarf. Well, it's green, literally, for 15 years and it still looks terrific. I'm emblematic. I like the blue label. I've got the purple label. And I think that, you know, Patrice lavey is Dino Mike. You got a winner there. Let's go to Anthony in Florida. Anthony.

[Caller (Arthur)]

Hey, Jim.

[Jim Cramer]

Booyah. Booyah. I'm Jim.

[Caller (Arthur)]

I'm a really big fan of opera. I think the company is trading at a cheap price relative to their fair value.

[Chris Byrne]

And I'd love to hear your thoughts.

[Jim Cramer]

I used to go to the opera. I liked Carmen and I like a lot of the German operas, but I don't know about opera. This opera. You stumped me. Let me do some work. I am going to go with my chief scientist, Ben Stoddo, find out what's going on there. Let's go to Tom in New York. Tom.

[Caller (Arthur)]

Booyah, Jimbo. Congrats to you birds and a lifelong suffering Jet fan here.

[Jim Cramer]

I, I, boy, I wish I could help you there, but there's a new coach from the Cowboys. He might be your man.

[Caller (Arthur)]

I think McCarthy's our man. Let's go. I'm ready.

[Jim Cramer]

Yeah.

[Caller (Arthur)]

I'm sorry.

[Jim Cramer]

No, that's just a huge believer in.

[Caller (Arthur)]

Aspen aerogel ticker symbol. They signed some super big contracts in 2024 with hopefully more to come. I want to load up, Jimbo.

[Jim Cramer]

Give me the green light. We're going to load up. I mean, it's a big cyclical stock that, you know, may be good, maybe bad. You need the Fed to cut. You need the Fed to cut rates 17 times for that to happen. Okay. I mean, maybe 42 times. I would be very slow in buying that stock. Let's go to Jacob, my home state of Pennsylvania. Jacob.

[Caller (Arthur)]

Hey, Jim. Thanks for having me on.

[Jim Cramer]

Absolutely. Go.

[Caller (Arthur)]

First opinion on Go Birds. I wanted to ask your opinion on Arbutus Biopharma picker Abus.

[Jim Cramer]

Okay. This is the ultimate spec. It's a three dollar stock. It loses money. You know, you could go to the casino, you could play in any kind of touchdown for a series of tight ends for the Eagles. Or you could buy our buttress. Take your buttress. Take, take your pick. How about Jacob in Alaska? Jacob.

[Caller (Arthur)]

Hey Jim, thanks for taking my call and for all that you and your team do. Long time listener club member, first time caller here.

[Jim Cramer]

Thank you.

[Caller (Arthur)]

As a frequent flyer I have a lot of experience with the major airlines and given your recent discussions on the sector, I know where you stand on Delta and United. Yes, I want to know your thoughts and longer term outlook on my hometown carrier. And best of breed along Alaska Airlines.

[Jim Cramer]

Oh man, they are so good. This is their moment. I think you have a total winner. I would stick with it. How about we go to Henry in New York? Henry.

[Caller (Arthur)]

Hey Professor Kramer, thanks for sharing your encyclopedic knowledge with us home gamers and.

[Jim Cramer]

Thank you for giving me tenure. What's going on?

[Caller (Arthur)]

Looking to add some M and a specific stock to my portfolio and looking at kkr but want to hear what your best in breed might be?

[Jim Cramer]

This wouldn't be Henry Kravis, would it? I mean is this Henry calling in or different Henry from New York? I'm going to bet it's not Henry Kravis. But I am going to say that I like the stock very much and I think those guys are so smart. I will be a buyer. Particularly at one point it was down really big. Today that made no sense to me whatsoever. Let's go to Walter in this never ending lightning round. Walter.

[Caller (Arthur)]

Jim, greatest talk from the Garden State right with you.

[Jim Cramer]

Oh man, I love the Garden State. I'm like all over it. What's going on?

[Caller (Arthur)]

I don't do well. I'll tell you. I'm a little bit at a conundrum. I've always thought of myself as a fairly intelligent guy. And about last year on your show a money manager recommended Crown Castle. I bought it way up there at about 113. It's dropped about 25%.

[Jim Cramer]

Why?

[Caller (Arthur)]

I don't know. It's got a great deal.

[Jeff Martha]

Okay.

[Caller (Arthur)]

The seven billion dollar thing didn't go through with tpg. They're not losing any revenue.

[Jim Cramer]

What's that? No, but the one thing I would say is I haven't had a money manager on the show and been on for 20 years. So I don't think a manager recommended that. And I have not liked Crown Castle for ages. So all I can say is don't look at me but stick with Kramer.

[Mad Money Producer]

The light lightning round is sponsored by Charles Schwab.

[Jim Cramer]

The gamification of the quantum computer socks finally wrapping up and all it took was a one, two punch from Nvidia's Jensen Huang and Meta's Mark Zuckerberg. To knock them to the canvas. In the most wide ranging interview I've seen in ages, the Joe Rogan Mark Zuckerberg Love Fast sir said, quoting I'm not really an expert on quantum computing, but my understanding is that it's still quite a ways off from being a truly practical paradigm. End quote. Very similar to what we heard from Jensen last week when he said it could be 20 or 30 years before we're using quantum computing commercially. Just a crushing blow to the jokers who take this stuff up. I for one am glad they popped the bubble because the quantum computing companies are such money losers and some of them were pretty darn quick by the way, to raise money at any price. Take Rigetti Computing, please. The company sold 50 million shares at 2 bucks just a few weeks ago, yet it traded $21 a week ago. We're plunging back to $6 and change today. What kind of craziness is that? So what was really going on here? I told investing club members that there's a game going on that has nothing to do with quantum computing. It's the Gamestop short busting story all over again. The gamers come in early, usually between 4 and 6am they buy and they buy and they buy some more. They catch short sellers unaware as no longs really up at that hour. The shorts think they're betting against them is easy money. Let's say the stocks trading at 30, okay? The Gamesters come in, they take it to 31 and 32, then 33, working it higher. The shorts figure that they can cover at the opening and make a few bucks. But instead what happens is the excited latecomers come flying in. They start paying 34, 35, 36. The early morning buyers ring the register as the shorts panic and cover. What a great trade. Except this time one and Zuckerberg wrecked everything by simply telling the truth as they know it about quantum computing, which is that it's probably not going to be commercially viable until I'm in my 90s. Look, it's painful to root against the people who buy stocks, whether it's quantum computing or small form nuclear reactors or clean energy. But the fact is, these moves never had anything to do with science. They were purely about the longs joining hands to nail the short sellers. I want this bloodsport game nipped in the bud. It's a classic case of froth. Fourth means top. We don't want top for heaven's sake. Which is why I was glad when the quantum computing bubble popped. There are so many things going wrong. Right now I worry about tariffs and taxes, bond auctions, sticky inflation, fed rate cut pauses. I can deal with those. What I can't deal with is this kind of unsustainable greed. I can't expect the CEOs of these speculative companies to say what Jensen and Mark said they would be stupid. But the fact is the insiders tend to jump on the opportunity to sell. That's exactly what happened during the dot com collapse in 20002001 when a lot of profitless companies saw their stocks explode higher only for them to be crushed by secondary robust insurance. Insider selling what followed was the worst bear market for growth stocks in years. I'm betting there will be a lot more losses once the air is totally out of the quantum balloon. So it's not too late, believe it or not, to sell. Given where these stocks came from, I'm hoping this will be a lesson that the Gamestop era is over. It's time for these buyers just to go to DraftKings or Fan J if they simply want to gamble, that's where this stuff belongs. Or to put it in a way these people might understand. These people are Putting on a 14 parlay of Rigetti quantum computing, IonQ and D wave Quantum. To which I say good luck. But it makes a lot more sense than what these chowderheads are doing now. Betting on the actual stocks at least trafficings is regulated to the fraudsters. I want to end this greed with a real good denouement, just like the one they're suffering right now. Here's your hat. Watch your heart. Don't let the door hit you on the way out. I like to say, as always, the bull market somewhere promise I find just for you right here on Mad Bunny. I'm Jim Cramer. See you tomorrow from San Francisco.

[Mad Money Producer]

All opinions expressed by Jim Cramer on this podcast are solely Kramer's opinions and do not reflect the opinions of CNBC, NBCUniversal, or their parent company or affiliates, and may have been previously disseminated by Kramer on television, radio, Internet, or another medium. You should not treat any opinion expressed by Jim Cramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Kremer's opinions are based upon information he considers reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Mad Money disclaimer, please visit cnbc.com madmoneydisclaimer when you're with Amex Business Platinum.

[Walmart Representative]

You have the card that works as hard as you do, with a flexible spending limit that adapts with your business. That's the powerful backing of American Express. Not all purchases will be approved. Terms apply. Learn [e-mail] AmEx Business.